EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR

Oras A Alabas, Kayleigh J Mason, Zenas Z N Yiu iD, Philip J Hampton, Nick J Reynolds, Caroline M Owen, Anthony Bewley, Philip M Laws, Richard B Warren iD, Mark Lunt, Catherine H Smith, Christopher E M Griffiths und 1 weitere

British Journal of Dermatology · 2023

DOI: 10.1093/bjd/ljad004 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Oras A Alabas und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Dermatology Research, University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, UK. Hauptthemen laut MEDLINE: Dermatologic Agents, Psoriasis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The University of Manchester, AbbVie, National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Real-world data evaluating effectiveness and persistence of systemic therapies for patients with psoriasis are limited.

Objectives

To determine the effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters (FAEs) and methotrexate in patients with moderate-to-severe psoriasis.

Methods

Data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), a prospective, multicentre pharmacovigilance register of patients with moderate-to-severe psoriasis receiving biologic and/or conventional systemic therapies, were analysed. Eligible patients were ≥ 16 years of age receiving a first course of acitretin, ciclosporin, FAEs or methotrexate between 2007 and 2021 with ≥ 6 months’ follow-up. Effectiveness was defined as achieving absolute Psoriasis Area and Severity Index (aPASI) ≤ 2 reported ≥ 4 weeks after treatment start date until date of cessation. To identify baseline clinical variables associated with treatment effectiveness, we used multivariable logistic regression models estimating the adjusted odds ratio (aOR) of achieving aPASI ≤ 2. To describe drug persistence associated with ineffectiveness, occurrence of adverse events or other reasons for discontinuation, survival estimates with 95% confidence intervals (CIs) were obtained using a flexible parametric model. Results were obtained using multiple imputed data.

Results

In total, 5430 patients were included in the analysis. Overall, 1023 (19%) patients were receiving acitretin, 1401 (26%) patients were on ciclosporin, 347 (6%) patients were on FAEs, and 2659 (49%) patients were receiving methotrexate at registration. The proportion of patients who achieved aPASI ≤ 2 was lower for those treated with acitretin [n = 118 (21%)] compared with those receiving ciclosporin [n = 233 (34%)], FAEs [n = 43 (29%)] and methotrexate [n = 372 (32%)]. Factors associated with ineffectiveness included prior experience to previous nonbiologic systemic therapies (acitretin) (aOR 0.64, 95% CI 0.42–0.96), male sex (methotrexate) (aOR 0.58, 95% CI 0.46–0.74), comorbidities (aOR 0.70, 95% CI 0.51–0.97) and alcohol consumption (≤ 14 units per week) (ciclosporin) (aOR 0.70, 95% CI 0.50–0.98). Persistence associated with all reasons for discontinuation showed better survival for methotrexate compared with acitretin, ciclosporin and FAEs cohorts at 12 months [survival estimate 46.1 (95% CI 44.0–48.3), 31.9 (95% CI 29.4–34.7), 30.0 (95% CI 27.5–32.4) and 35.0 (95% CI 29.9–40.9), respectively].

Conclusions

The real-world effectiveness and persistence of acitretin, ciclosporin, FAEs and methotrexate were generally low. Previous nonbiologic systemic therapies, male sex, comorbidities and alcohol consumption were risk factors associated with treatment ineffectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatologic AgentsPsoriasisHumansMaleMethotrexateAcitretinCyclosporineCohort StudiesProspective StudiesFumaratesBiological FactorsImmunologic FactorsAdjuvants, ImmunologicTreatment Outcome

Substanzen

MethotrexateAcitretinCyclosporineFumaratesDermatologic AgentsBiological FactorsImmunologic FactorsAdjuvants, Immunologic

Autor:innen und Institutionen

  • Centre for Dermatology Research, University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, UK.
  • Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, UK.
  • Institute of Translational and Clinical Medicine, Medical School, Newcastle University, Department of Dermatology, Royal Victoria Infirmary and NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals NHS Foundati…
  • Department of Dermatology, Royal Blackburn Teaching Hospital, East Lancashire Hospitals NHS Trust, Blackburn, UK.
  • Barts Health NHS Trust & Queen Mary University, London, UK.
  • Leeds Dermatology Centre, Leeds Teaching Hospitals NHS Trust, Chapeltown Road, Leeds, UK.

ORCID-Profile: Zenas Z N Yiu, Richard B Warren

Förderung

  • The University of Manchester
  • AbbVie
  • National Institute for Health and Care Research

Zitieren

APA

Alabas, O. A., Mason, K. J., Yiu, Z. Z. N., Hampton, P. J., Reynolds, N. J., Owen, C. M., Bewley, A., Laws, P. M., Warren, R. B., Lunt, M., Smith, C. H., Griffiths, C. E. M., & BADBIR Study Group (2023). Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad004

Vancouver

Alabas OA, Mason KJ, Yiu ZZN, Hampton PJ, Reynolds NJ, Owen CM, et al. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad004

BibTeX
@article{Alabas2023,
  author = {Alabas, Oras A and Mason, Kayleigh J and Yiu, Zenas Z N and Hampton, Philip J and Reynolds, Nick J and Owen, Caroline M and Bewley, Anthony and Laws, Philip M and Warren, Richard B and Lunt, Mark and Smith, Catherine H and Griffiths, Christopher E M and BADBIR Study Group, BADBIR Study Group},
  title = {Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR},
  journal = {British Journal of Dermatology},
  year = {2023},
  doi = {10.1093/bjd/ljad004}
}
Kostenlos starten →